Weight & GLP-1
Semaglutide + Cagrilintide
CagriSema: the best-studied combination here
In this stack
SeSemaglutideGLP-1 receptor agonistWeight & GLP-1›CaCagrilintideLong-acting amylin analogueWeight & GLP-1›
Why people pair them
Semaglutide copies GLP-1, a gut fullness hormone. Cagrilintide copies amylin, a different fullness hormone released alongside insulin. They act on different brain pathways that both reduce appetite, so together they were expected to do more than either alone.
What the research shows
This is the one combination in this list tested in large trials. In REDEFINE 1, the combination led to about 20% average weight loss over 68 weeks, more than either medicine alone. It is being developed by a pharmaceutical company as a single product and is not approved at the time of writing.
Extra things to consider
- Stomach side effects (nausea, vomiting, constipation) are common and can be stronger together
- The same thyroid and pancreatitis cautions as other GLP-1 medicines
- Trial results come from a specific, supervised product, not separate vials combined at home
Ask your doctor
- Am I eligible for a trial or an approved option?
- How would side effects be managed?
Key references (1)
- Garvey et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). NEJM, 2025.
General information, not advice, and not a recommendation to combine anything. Talk to a qualified healthcare professional before starting, changing or combining anything.